Richard Malabre - Akebia Ther Chief Officer
| AKBA Stock | USD 1.93 0.05 2.66% |
Executive
Richard Malabre is Chief Officer of Akebia Ther
| Age | 63 |
| Address | 245 First Street, Cambridge, MA, United States, 02142 |
| Phone | 617 871 2098 |
| Web | https://www.akebia.com |
Akebia Ther Management Efficiency
The company has return on total asset (ROA) of (0.0937) % which means that it has lost $0.0937 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5345) %, meaning that it created substantial loss on money invested by shareholders. Akebia Ther's management efficiency ratios could be used to measure how well Akebia Ther manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 1.78, whereas Return On Tangible Assets are forecasted to decline to (0.37). At present, Akebia Ther's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 182 M, whereas Other Current Assets are forecasted to decline to about 12.6 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kevin CPA | Enveric Biosciences | 60 | |
| JD Esq | Seres Therapeutics | 69 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Patrick Mayo | Hepion Pharmaceuticals | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| MD JD | Cidara Therapeutics | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| SPHR CCP | Cidara Therapeutics | N/A | |
| MD MBA | Ocean Biomedical | 59 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Esq CPA | Ocean Biomedical | 59 | |
| RPh Young | Seres Therapeutics | 57 | |
| Yael Fellous | Protalix Biotherapeutics | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Candice Masse | Elevation Oncology | N/A | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Taylor Sandison | Cidara Therapeutics | 52 | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| John Cavan | Hepion Pharmaceuticals | 66 | |
Management Performance
| Return On Equity | -5.53 | ||||
| Return On Asset | -0.0937 |
Akebia Ther Leadership Team
Elected by the shareholders, the Akebia Ther's board of directors comprises two types of representatives: Akebia Ther inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Akebia. The board's role is to monitor Akebia Ther's management team and ensure that shareholders' interests are well served. Akebia Ther's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Akebia Ther's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Burke, Senior Vice President Chief Medical Officer | ||
| Mercedes Carrasco, Director Communications | ||
| David Spellman, CFO VP | ||
| Tracey Vetterick, Vice Administration | ||
| Nicole Hadas, Sr. VP, General Counsel and Secretary | ||
| Thierry Bilbault, VP Devel | ||
| Kristie Bolieau, VP Controller | ||
| Erik MBA, Senior Officer | ||
| Michel Dahan, Senior Vice President and Chief Business Officer | ||
| Douglas MBA, Vice Strategy | ||
| Nicole JD, Chief VP | ||
| Nicholas Grund, Senior Officer | ||
| Carolyn Rucci, Senior Counsel | ||
| Kimberly Garko, Senior Officer | ||
| John MBA, President, CEO | ||
| Meredith Bowman, Senior Officer | ||
| Steven MD, Senior Officer | ||
| Richard Malabre, Chief Officer | ||
| CGMA CPA, CFO VP | ||
| Violetta Cotreau, Chief VP |
Akebia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Akebia Ther a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -5.53 | ||||
| Return On Asset | -0.0937 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | (0.33) % | ||||
| Current Valuation | 424.74 M | ||||
| Shares Outstanding | 218.18 M | ||||
| Shares Owned By Insiders | 2.09 % | ||||
| Shares Owned By Institutions | 27.28 % | ||||
| Number Of Shares Shorted | 14.84 M | ||||
| Price To Earning | (4.84) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Akebia Ther offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Akebia Ther's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Akebia Ther Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Akebia Ther Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Akebia Ther. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. For information on how to trade Akebia Stock refer to our How to Trade Akebia Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Akebia Ther. If investors know Akebia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Akebia Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.22) | Revenue Per Share 0.834 | Quarterly Revenue Growth (0.11) | Return On Assets (0.09) | Return On Equity (5.53) |
The market value of Akebia Ther is measured differently than its book value, which is the value of Akebia that is recorded on the company's balance sheet. Investors also form their own opinion of Akebia Ther's value that differs from its market value or its book value, called intrinsic value, which is Akebia Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Akebia Ther's market value can be influenced by many factors that don't directly affect Akebia Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Akebia Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine if Akebia Ther is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Akebia Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.